IN2014MN01577A - - Google Patents
Info
- Publication number
- IN2014MN01577A IN2014MN01577A IN1577MUN2014A IN2014MN01577A IN 2014MN01577 A IN2014MN01577 A IN 2014MN01577A IN 1577MUN2014 A IN1577MUN2014 A IN 1577MUN2014A IN 2014MN01577 A IN2014MN01577 A IN 2014MN01577A
- Authority
- IN
- India
- Prior art keywords
- group
- alkyl group
- alkoxy
- alkyl
- halogenated
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Provided is a drug for the treatment and/or prevention of pain or a drug for the treatment and/or prevention of sodium channel mediated diseases. A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: Ar Ar: heteroaryl group aryl group; R R R: hydrogen atom halogen atom C1 C6 alkyl group halogenated C1 C6 alkyl group hydroxy C1 C6 alkyl group C1 C6 alkoxy C1 C6 alkyl group or C3 C7 cycloalkyl group cyano group; R R: hydrogen atom halogen atom C1 C6 alkyl group halogenated C1 C6 alkyl group hydroxyl group hydroxy C1 C6 alkyl group C1 C6 alkoxy C1 C6 alkyl group C3 C7 cycloalkyl group C1 C6 alkoxy group; n: integer from 1 to 3; the heteroaryl group and aryl group may have one or two groups selected independently from a halogen atom C1 C6 alkyl group halogenated C1 C6 alkyl group hydroxyl group hydroxy C1 C6 alkyl group C1 C6 alkoxy C1 C6 alkyl group C3 C7 cycloalkyl group carboxyl group cyano group amino group C1 C3 alkylamino group and di C1 C3 alkylamino group; in the case of two the two may be the same or different.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012025754 | 2012-02-09 | ||
| JP2012259122 | 2012-11-27 | ||
| PCT/JP2013/052985 WO2013118854A1 (en) | 2012-02-09 | 2013-02-08 | Cycloalkane derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01577A true IN2014MN01577A (en) | 2015-05-08 |
Family
ID=48947609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1577MUN2014 IN2014MN01577A (en) | 2012-02-09 | 2013-02-08 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8889741B2 (en) |
| EP (2) | EP2813491B1 (en) |
| JP (2) | JP5997710B2 (en) |
| KR (1) | KR20140127238A (en) |
| CN (1) | CN104185629B (en) |
| AU (1) | AU2013218592B2 (en) |
| BR (1) | BR112014019478A2 (en) |
| CA (1) | CA2864222C (en) |
| CO (1) | CO7151511A2 (en) |
| CY (1) | CY1118572T1 (en) |
| DK (1) | DK2813491T3 (en) |
| ES (2) | ES2613078T3 (en) |
| HR (1) | HRP20161713T1 (en) |
| HU (2) | HUE031450T2 (en) |
| IL (1) | IL234014A (en) |
| IN (1) | IN2014MN01577A (en) |
| LT (1) | LT2813491T (en) |
| MX (1) | MX349354B (en) |
| NZ (1) | NZ628096A (en) |
| PH (2) | PH12014501804A1 (en) |
| PL (1) | PL2813491T3 (en) |
| PT (1) | PT2813491T (en) |
| RS (1) | RS55671B1 (en) |
| RU (1) | RU2635354C2 (en) |
| SG (1) | SG11201404707VA (en) |
| SI (1) | SI2813491T1 (en) |
| SM (2) | SMT201700053T1 (en) |
| TW (1) | TWI612042B (en) |
| WO (1) | WO2013118854A1 (en) |
| ZA (1) | ZA201405801B (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2773641B1 (en) | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| WO2013064983A1 (en) * | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| SG11201408284VA (en) | 2012-05-22 | 2015-02-27 | Xenon Pharmaceuticals Inc | N-substituted benzamides and their use in the treatment of pain |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| RU2015143906A (en) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | SUBSTITUTED TRIAZOLOPYRIDINES AND WAYS OF THEIR APPLICATION |
| BR112015022385A2 (en) * | 2013-03-14 | 2017-07-18 | Daiichi Sankyo Co Ltd | drug for a respiratory disease |
| US9493429B2 (en) | 2013-03-15 | 2016-11-15 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| AU2014356967A1 (en) | 2013-11-27 | 2016-07-07 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JP2017525677A (en) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | Therapeutic compounds and methods of use thereof |
| BR112017024853A2 (en) | 2015-05-22 | 2018-08-07 | Genentech Inc | compound, pharmaceutical composition, method for treating a disease or condition in a mammal, for treating itching in a mammal, for treating or prophylaxis and use of a compound |
| MA42683A (en) | 2015-08-27 | 2018-07-04 | Genentech Inc | THERAPEUTIC COMPOUNDS AND THEIR METHODS OF USE |
| SG10202007787RA (en) | 2015-09-28 | 2020-09-29 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| KR20180080187A (en) * | 2015-11-06 | 2018-07-11 | 다이이찌 산쿄 가부시키가이샤 | Decomposition method of dimethoxybenzyl group |
| JP2018535234A (en) | 2015-11-25 | 2018-11-29 | ジェネンテック， インコーポレイテッド | Substituted benzamides useful as sodium channel blockers |
| WO2017172802A1 (en) | 2016-03-30 | 2017-10-05 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| ES3022639T3 (en) * | 2016-05-20 | 2025-05-28 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| SG11201903348UA (en) * | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| EP3532462B1 (en) * | 2016-10-27 | 2021-10-13 | Bristol-Myers Squibb Company | Acyl sulfonamide nav1.7 inhibitors |
| CN110325531B (en) * | 2016-12-09 | 2022-05-27 | 泽农医药公司 | Benzenesulfonamides and their use as therapeutic agents |
| CN110546148A (en) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 4-piperidine-N- (pyrimidin-4-yl) chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| KR102796209B1 (en) | 2017-09-20 | 2025-04-16 | 에이비엠 쎄라퓨틱스 코포레이션 | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| EP3759098A1 (en) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| CN111936494A (en) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | Substituted hydrogen-pyrido-azines as sodium channel inhibitors |
| TW202003490A (en) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | Therapeutic compounds and methods of use thereof |
| BR112020024729A2 (en) | 2018-06-13 | 2021-03-23 | Xenon Pharmaceuticals, Inc. | benzenesulfonamide compounds and their use as therapeutic agents |
| MA53488A (en) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | HETEROARYL SUBSTITUTED SULPHONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS |
| IL279810B2 (en) | 2018-08-31 | 2025-03-01 | Xenon Pharmaceuticals Inc | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
| CN113164461A (en) * | 2018-12-26 | 2021-07-23 | 拉夸里亚创药株式会社 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers |
| US20240241265A1 (en) * | 2023-01-18 | 2024-07-18 | Qualcomm Incorporated | Virtual positioning signal measurements |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6222048B1 (en) | 1995-12-18 | 2001-04-24 | Merck Frosst Canada & Co. | Diaryl-2-(5H)-furanones as Cox-2 inhibitors |
| WO2006038594A1 (en) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N-type calcium channel inhibitor |
| MX2007014486A (en) * | 2005-05-16 | 2008-02-12 | Vertex Pharma | Bicyclic derivatives as modulators of ion channels. |
| WO2009012242A2 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| WO2010035166A1 (en) | 2008-09-23 | 2010-04-01 | Pfizer Limited | Benzamide derivatives |
| EA020460B1 (en) * | 2009-01-12 | 2014-11-28 | Пфайзер Лимитед | Sulfonamide derivatives |
| US9096558B2 (en) | 2010-07-09 | 2015-08-04 | Pfizer Limited | N-sulfonylbenzamide compounds |
| ES2533065T3 (en) * | 2010-07-09 | 2015-04-07 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| ES2532356T3 (en) * | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonylbenzamides as voltage dependent sodium channel inhibitors |
| WO2013064983A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
-
2013
- 2013-01-31 US US13/756,173 patent/US8889741B2/en active Active
- 2013-02-07 TW TW102104725A patent/TWI612042B/en not_active IP Right Cessation
- 2013-02-08 HU HUE13746373A patent/HUE031450T2/en unknown
- 2013-02-08 ES ES13746373.3T patent/ES2613078T3/en active Active
- 2013-02-08 HR HRP20161713TT patent/HRP20161713T1/en unknown
- 2013-02-08 SG SG11201404707VA patent/SG11201404707VA/en unknown
- 2013-02-08 BR BR112014019478A patent/BR112014019478A2/en not_active Application Discontinuation
- 2013-02-08 HU HUE16193142A patent/HUE037048T2/en unknown
- 2013-02-08 CN CN201380017715.1A patent/CN104185629B/en not_active Expired - Fee Related
- 2013-02-08 EP EP13746373.3A patent/EP2813491B1/en active Active
- 2013-02-08 SI SI201330423A patent/SI2813491T1/en unknown
- 2013-02-08 WO PCT/JP2013/052985 patent/WO2013118854A1/en not_active Ceased
- 2013-02-08 MX MX2014009637A patent/MX349354B/en active IP Right Grant
- 2013-02-08 LT LTEP13746373.3T patent/LT2813491T/en unknown
- 2013-02-08 DK DK13746373.3T patent/DK2813491T3/en active
- 2013-02-08 EP EP16193142.3A patent/EP3144300B1/en not_active Not-in-force
- 2013-02-08 ES ES16193142.3T patent/ES2659434T3/en active Active
- 2013-02-08 PT PT137463733T patent/PT2813491T/en unknown
- 2013-02-08 IN IN1577MUN2014 patent/IN2014MN01577A/en unknown
- 2013-02-08 JP JP2013557586A patent/JP5997710B2/en not_active Expired - Fee Related
- 2013-02-08 AU AU2013218592A patent/AU2013218592B2/en not_active Ceased
- 2013-02-08 KR KR1020147021798A patent/KR20140127238A/en not_active Abandoned
- 2013-02-08 RU RU2014136463A patent/RU2635354C2/en not_active IP Right Cessation
- 2013-02-08 SM SM20170053T patent/SMT201700053T1/en unknown
- 2013-02-08 RS RS20170101A patent/RS55671B1/en unknown
- 2013-02-08 NZ NZ628096A patent/NZ628096A/en not_active IP Right Cessation
- 2013-02-08 PL PL13746373T patent/PL2813491T3/en unknown
- 2013-02-08 CA CA2864222A patent/CA2864222C/en not_active Expired - Fee Related
-
2014
- 2014-08-06 ZA ZA2014/05801A patent/ZA201405801B/en unknown
- 2014-08-07 IL IL234014A patent/IL234014A/en not_active IP Right Cessation
- 2014-08-11 PH PH12014501804A patent/PH12014501804A1/en unknown
- 2014-09-05 CO CO14195847A patent/CO7151511A2/en unknown
- 2014-09-30 US US14/502,708 patent/US9493448B2/en not_active Expired - Fee Related
-
2015
- 2015-11-27 PH PH12015502675A patent/PH12015502675A1/en unknown
-
2016
- 2016-08-26 JP JP2016165515A patent/JP6154052B2/en not_active Expired - Fee Related
- 2016-09-19 US US15/269,485 patent/US9845313B2/en not_active Expired - Fee Related
-
2017
- 2017-01-24 SM SM201700053T patent/SMT201700053B/en unknown
- 2017-01-31 CY CY20171100142T patent/CY1118572T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01577A (en) | ||
| IN2014DN03063A (en) | ||
| NZ703064A (en) | Inhibitors of hepatitis c virus | |
| MX2014015158A (en) | Pyridinone and pyridazinone derivatives. | |
| IN2014MN01754A (en) | ||
| MY198204A (en) | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof | |
| PH12014500842A1 (en) | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection | |
| TN2013000293A1 (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
| MX362550B (en) | Heterocyclic inhibitors of glutaminase. | |
| IN2014MN00988A (en) | ||
| IN2014MN02652A (en) | ||
| IN2015DN01119A (en) | ||
| NZ607580A (en) | N-heteroaryl compounds | |
| MX2011011083A (en) | Heterocyclic compounds as mek inhibitors. | |
| MY169485A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| MY165902A (en) | Substituted pyridine derivatives as fabi inhibitors | |
| TN2015000293A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
| MX350418B (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders. | |
| MX2011009709A (en) | Compounds for treating inflammation and pain. | |
| WO2013106761A3 (en) | Antimicrobial agents | |
| MX2013008340A (en) | Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer. | |
| PH12012501552A1 (en) | Therapeutic or prophylactic agent for biliary diseases | |
| PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| IN2014DN11023A (en) | ||
| NZ700507A (en) | Pyrimidine derivatives for the treatment of bacterial diseases |